Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · REGISTER · 2004-04-13 · Food and Drug Administration, HHS · Notices

Notices. Notice of public workshop

474 words·~2 min read·/register/2004/04/13/04-8251

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Fifth Joint Project Management Workshop on Improving Agency/Industry Communication Throughout the Drug Development Process; Public Workshop AGENCY: Food and Drug Administration, HHS. ACTION: Notice of public workshop. The Food and Drug Administration
(FDA)in cosponsorship with the Drug Information Association
(DIA)is announcing a public workshop entitled “The Fifth Joint Project Management Workshop: Improve Agency/Industry Communication Throughout the Drug Development Process.” The workshop will focus on facilitating the drug development and drug review processes through interactions between industry and FDA to effectively manage risk to expedite products of public benefit to market. *Date and Time* : The public workshop will be held on May 11, 2004, from 8:30 a.m. to 5 p.m., May 12, 2004, from 8:30 a.m. to 5 p.m., and May 13, 2004, from 8:30 a.m. to 12:30 p.m. *Location* : The public workshop will be at the Hyatt Regency Bethesda, 1 Bethesda Metro Center, Bethesda, MD. *Contact Person* : Julieann Dubeau, Center for Drug Evaluation and Research (HFD-180), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD, 301-827-7310, FAX: 301-827-1305, e-mail: *Dubeau@cder.fda.gov* , or Gail Sherman, Center for Biologics Evaluation and Research (HFM-42), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-2000, FAX: 301-827-3079, e-mail: *Sherman@cber.fda.gov* , or Camela Pastorius, Drug Information Association, 800 Enterprise Rd., suite 200, Horsham, PA 19044, 215-442-6196, FAX: 215-442-6103, e-mail: *Camela.Pastorius@diahome.org* . *Registration* : Mail or fax your registration information and registration fee to Drug Information Association (DIA), P.O. Box 827192, Philadelphia, PA 19182-7192. You may obtain registration forms from DIA (see *Contact Person* ) or from FDA at *http://www.fda.gov/cber/meetings.htm* . Additional information regarding registration fees and online registration can be found at *http://www.diahome.org/docs/events/events_search_detail.cfm* . (FDA has verified the Web site, but we are not responsible for subsequent changes to the Web site after this document publishes in the **Federal Register** .) If you need special accommodations due to a disability, please contact Camela Pastorius (see *Contact Person* ) by May 4, 2004. SUPPLEMENTARY INFORMATION: FDA (the Center for Biologics Evaluation and Research and the Center for Drug Evaluation and Research) and DIA are cosponsoring a public workshop as part of a continuing effort to develop higher levels of teamwork, communication, and procedural knowledge to facilitate drug development and review in the United States. The workshop's target audience is project directors, leaders, managers, and regulatory affairs representatives from industry; and FDA reviewers, regulatory project managers, and consumer safety officers. At the conclusion of the workshop, the participants should be able to do the following:
(1)Identify FDA/industry cultural differences that influence interactions between the two groups,
(2)effectively manage constructive interactions in a changing environment, and
(3)manage communication strategies for facilitating drug approvals. Dated: April 6, 2004. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. 04-8251 Filed 4-12-04; 8:45 am]
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.